ERAS-601 + pembrolizumab

ERAS-601 + pembrolizumab is an investigational combination therapy under clinical evaluation for advanced or metastatic solid tumors. ERAS-601 is a potent, selective, orally bioavailable allosteric inhibitor of SHP2 (encoded by PTPN11), a protein tyrosine phosphatase critical for signaling downstream of multiple receptor tyrosine kinases, including the RAS/MAPK pathway. Pembrolizumab is a well-established, FDA-approved monoclonal antibody and immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), thereby enhancing antitumor immune response. The combination aims to simultaneously inhibit tumor growth signaling and reinvigorate immune responses against cancer cells. Early-phase trials are focused on safety, tolerability, optimal dosing, and preliminary efficacy in advanced or metastatic solid tumors[3][5].

Other names

SHP2 inhibitor + pembrolizumab